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Abstract
Polymerization of the amyloid L-peptide (AL) has been identified as a major feature of the pathogenesis of Alzheimer’s
disease (AD). Inhibition of the formation of these toxic polymers of AL has thus emerged as an approach to developing
therapeutics for AD. Techniques for studying AL polymerization include the use of fibril nucleation and extension assays in a
variety of formats. Detection of polymeric forms of AL has been achieved using turbidity, dye binding, light scattering and
toxicity among other methods. Direct and indirect methods have been described for the measurement of binding affinities for
AL fibrils. Imaging techniques include electron microscopy, X-ray diffraction and atomic force microscopy. These techniques
have been used to characterize different classes of compounds that inhibit the formation of AL polymers. These compounds
include dyes such as Congo Red, the antibiotic rifampicin, the anthracycline 4P-iodo-4P-deoxydoxorubicin, and a large
variety of AL-derived peptides and modified peptides, among other reported inhibitors. ß 2000 Elsevier Science B.V. All
rights reserved.
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1. Introduction
Polymerization of the amyloid L-peptide (AL) has
been identi¢ed as a major feature of the pathogenesis
of Alzheimer’s disease (AD) [1,2]. Consistently, in-
creased risk for disease is associated with conditions
that support increased formation of polymerized AL
[3,4]. Monomeric AL is produced during normal me-
tabolism and appears to have no deleterious e¡ects
on neurons [5,6] and the amyloid precursor protein
(APP) has been shown to have memory enhancing
properties in mice [7,8]. As AL assembles into oligo-
meric forms and eventually into the amyloid ¢brils
that are deposited in the neuritic plaques character-
istic of AD, it acquires high neuronal toxicity [9^16].
Inhibition of the formation of these toxic polymers
of AL has thus emerged as an approach to develop-
ing therapeutics for AD [17,18].
De¢nitive treatment or cure of AD does not cur-
rently exist. The available therapies, cholinesterase
inhibitors, modestly delay the progression of disease
and near-term goals for therapy may have to be lim-
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ited to continued improvements in slowing disease
rather than eradicating it [19]. Additional modes of
therapeutic intervention are under active or proposed
clinical evaluation. Inhibition of the formation of
toxic forms of AL is one of these approaches that
is still waiting to be tested in the clinic.
Lansbury has extensively discussed the amyloid
hypothesis of AD, evidence for and against it, and
four approaches to therapeutic intervention based on
current knowledge of AD pathogenesis and AL bio-
chemistry [18] : (1) inhibit expression of APP; (2)
inhibit production of AL peptide(s); (3) inhibit amy-
loid ¢bril formation; (4) inhibit the toxicity of AL
¢brils. Inhibition of the formation of toxic polymeric
AL targets what is believed to be a singularly patho-
logical event, and is therefore viewed as a preferred
therapeutic strategy [18]. This article reviews re-
ported inhibitors of AL polymerization and assays
used to characterize them.
2. AL peptide
Historically, working with full-length AL of 39^43
residues in length was di⁄cult because of variations
in the properties of di¡erent preparations of the pep-
tide. Characterization of preparations by their neuro-
toxicity used to be the norm until it became apparent
that properly prepared AL should be non-toxic to
begin with. At present, numerous laboratories both
commercial and academic have demonstrated the
ability to synthesize, purify and store AL peptides
of consistent quality. Most AD researchers are using
the 40 and 42 residue lengths of AL as the major
forms to work with. The shorter form is the primary
length in circulation and is also easier to synthesize
and purify. The longer form is believed to be more
signi¢cant in pathogenesis but is harder to prepare
and use in some assays. With respect to polymeriza-
tion inhibitors, most inhibitors of one peptide are
expected to act on the other with the exception of
something like an AL1ÿ42 C-terminal speci¢c anti-
body. Testing a compound of particular interest on
both peptides is preferred, however. As for using
truncated AL fragments, of which AL1ÿ28 and
AL25ÿ35 have been popular in the past, it seems ill-
advised to use them because of their di¡erences from
the documented major in vivo pathological forms.
3. Assays
There are two general forms of assay for AL poly-
merization, ¢bril nucleation and ¢bril extension [20^
22]. Fibril binding can also be measured. Di¡erent
laboratories cited in the text have implemented these
types of assays in a variety of ways. Fibril nucleation
assays measure the time required for a solution of
initially monomeric AL to form nuclei to initiate ¢-
brillogenesis and the extent of ¢bril formation that
ensues. Fibril formation can be measured by appar-
ent absorbance in an ultraviolet/visible spectrometer
([20] and references therein) or by right-angle light
scattering in a £uorimeter, by dye binding [23^26],
and by measurement of the toxicity of the ¢bril so-
lution. Fibril extension assays are similar to nuclea-
tion except that the solution of AL monomer is
seeded at the beginning of the assay with a small
amount of preformed AL ¢bril. This added ¢bril
seeds the formation of additional ¢brils immediately
without the delay or lag observed in the nucleation
assay. Fibril or plaque binding assays have been per-
formed in several di¡erent formats. Typically, a
known ligand is radiolabeled and a competition as-
say is performed, monitoring displacement of the la-
bel by a test compound [27,28]. An alternative ap-
proach is to measure the binding of labeled AL to
solid-phase test compound [29]. Light scattering has
also been used to monitor AL ¢brillogenesis ([30,31]
and references therein). For general use, a nucleation
assay combined with a cell toxicity assay may repre-
sent the best approach to screening compounds.
While unsuited to high throughput assays, electron
microscopy (EM) has been widely used to document
the absence or presence of ¢brillar AL. X-ray di¡rac-
tion has also been used to characterize amyloid ¢brils
[32,33]. Atomic force microscopy has been demon-
strated to be extraordinarily e¡ective for imaging
amyloid ¢brils and preliminary data indicate that
this technique is useful in studying the mechanism
of ¢bril assembly [34^37].
4. Congo Red (CR) and analogs
CR is a histological azo dye commonly used to
identify amyloid plaque because of the characteristic
birefringence of ¢brils stained with it (CR, 1). CR is
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also reported to inhibit the toxicity of AL1ÿ40 by
blocking ¢bril formation and by binding to pre-
formed ¢brils and reducing their toxicity [38]. For
AL1ÿ42, CR blocked the toxicity of ¢brils but did
not prevent their formation [38]. In a more recent
study, CR was reported to increase monomer/oligo-
mer ratios in cell culture by stabilizing AL monomer
to aggregation rather than by promoting an increase
in AL formation or inhibiting AL degradation [39].
An ED50 of 3.4 WM CR was reported e¡ective to
inhibit the toxicity of V10 nM AL at a V300 molar
excess of CR. The dissociation constant of CR from
AL1ÿ40 ¢brils in a competition assay has been re-
ported to be 0.5 WM [27], comparable to its potency
in cell culture. It is noteworthy that a patent has
been issued for the use of CR to treat various forms
of amyloid disease [40].
Analogs of CR have been reported resulting from
e¡orts to make potential diagnostic agents for AD
based on imaging amyloid plaque. Chrysamine G
(CG), a CR analog in which the sulfonate groups
are replaced by carboxylates, was prepared as a
more lipophilic compound [41] with a greater poten-
tial brain availability. The binding a⁄nity of CG to
AL10ÿ43 was determined to be 0.4 WM using a com-
petition assay. CG was also reported to inhibit the
polymerization-associated toxicity of the small 25^35
fragment of AL at a concentration of s 0.2 WM on
PC12 cells [42]. Other analogs of CR and CG pre-
pared as potential single-photon emission computer-
ized tomography imaging agents have been described
[27]. These compounds contain bipyridyl moieties to
chelate technetium and were characterized based on
their ability to bind to AL1ÿ40 ¢brils. The free bipyr-
idyl analogs and technetium^tetrakis(t-butylisocya-
nide) complexes had dissociation constants of 0.16^
0.76 WM.
1
5. Rifampicin and other rifamycins
The rifamycins are a group of naphthohydroqui-
none-containing antibiotics. Observations that lep-
rosy patients had a reduced risk of AD ([43] and
references therein, but see also [44]) resulted in the
identi¢cation of the anti-leprosy drug rifampicin (2)
as an AL polymerization inhibitor [45,46]. Fibril for-
mation in vitro and toxicity to PC12 cells was inhib-
ited by a V5-fold molar excess of 2 and several
analogs and, in a subsequent study, additional ana-
logs of 2 were studied to explore the SAR for inhi-
bition [47]. The standard thio£avine T (Th-T) dye
binding assay was used to observe dose-dependent
inhibition of aggregation and toxicity and EM was
used to monitor the reduction of ¢bril formation in
inhibited mixtures. The SAR pro¢le of the rifamycins
suggests that inhibition results from the inclusion of
the naphthohydroquinone/naphthoquinone moiety.
While this group has radical scavenging properties
which are associated with protective e¡ects in AD
patients, the pro¢le of these inhibitors is similar to
others that seem most likely to act by direct binding
to AL.
2
6. 4P-Iodo-4P-deoxydoxorubicin (IDOX)
IDOX (3) is an analog of the anthracycline anti-
cancer agent doxorubicin. In a clinical trial for the
treatment of amyloid light-chain disease, unexpected
anti-amyloidogenic e¡ects suggested the examination
of the in vitro amyloid binding properties of IDOX
[48]. IDOX was found to bind with high a⁄nity to
¢ve di¡erent types of natural amyloid ¢brils includ-
ing that of AL. Insulin ¢bril binding competition
studies indicated structurally distinct binding sites
for IDOX and CR. In the Syrian hamster prion dis-
ease model, IDOX-pretreated scrapie-infected brain
homogenate was slower to induce disease and re-
sulted in increased survival times [49]. A challenge
in the therapeutic application of IDOX is its toxicity
and analogs with improved safety are probably re-
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quired for clinical development as anti-amyloid
agents.
3
7. Acridinones
A screening program at Parke-Davis identi¢ed a
class of 9-acridinone derivatives with anti-aggrega-
tion activity [50]. These compounds were previously
discovered as anti-bacterial and anti-tumor agents
and apparently were available from the company’s
compound inventory. Inhibition of L-amyloid aggre-
gation was performed using a 0.2 Wm ¢ltration-based
assay in which AL1ÿ40 was initially dissolved in hexa-
£uoroisopropanol and diluted to a ¢nal concentra-
tion of 40 WM in sodium phosphate bu¡er. In this
assay, 1-(3-dimethylaminopropyl-1-amino)-4-nitro-7-
methylmercapto-9-acridinone (4) was reported to
have an IC50 of 7.1 WM. An assay for inhibition of
AL deposition onto human brain tissue is also de-
scribed brie£y in this patent.
4
8. Benzofurans
A SmithKline Beecham group has reported a series
of benzofuran derivatives that inhibit ¢bril formation
[51]. A representative potent inhibitor SKF-74652, 5,
was characterized in several di¡erent assays. In a
¢brillogenesis inhibition assay based on an immuno-
assay readout and in an AL binding assay based on
scintillation proximity, the IC50 values observed were
28 WM and 11 WM, respectively. The concentration of
AL1ÿ40 in these assays was 11.6 WM, suggesting that
the inhibitor may bind even more tightly than sug-
gested by the determined potency in the binding as-
say.
5
9. Peptides
E¡orts to understand the basis for the ¢brillogenic
nature of AL have resulted in a variety of studies in
which analogs of AL were synthesized and their abil-
ity to form amyloid ¢brils evaluated. Among these
studies was a report that showed that substitution of
the phenylalanyl^phenylalanyl dipeptide at positions
19^20 in the AL sequence could produce peptides
that had increased solubilities [52]. In combination
with native-sequence AL, the Phe-substituted analogs
inhibited formation of amyloid ¢brils [52]. This result
showed how a large AL peptide could have decreased
amyloidogenicity by altering this hydrophobic core
region. Such peptides are of limited interest for ther-
apeutic development because of their large size and
presumed limited bioavailability and biostability. A
related approach is to take advantage of the impor-
tance of the Phe^Phe sequence and adapt it to the
design of inhibitors. Several groups have pursued this
strategy.
Early studies with organic-modi¢ed peptides estab-
lished the feasibility of using peptides derived from
fragments of AL as inhibitors [53,54]. Combining an
organic modi¢er with an AL binding peptide se-
quence a¡orded potent and selective inhibitors such
as cholyl-LVFFA-OH (6) [55^60]. An equimolar
concentration of this compound in the range of
0.2V50 WM monomeric AL1ÿ40 blocked ¢bril forma-
tion inde¢nitely and at lower concentrations, it was
able to signi¢cantly delay ¢bril formation and exten-
sion assays were potently inhibited in a similar man-
ner [56]. Testing of assay mixtures in cell culture
showed that the delay in polymerization corre-
sponded to a delay in the formation of toxic forms
of AL. Extension of this work demonstrated that
organic-modi¢ed all-D [59^61] and sequence-modi-
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¢ed AL-derived all-D peptides [61] are potent inhib-
itors of AL polymerization and toxicity. LVFFA-
based compounds with increased potency have been
obtained by substitution of the alanyl residue with a
larger hydrophobic residue such as leucine. These
substitutions were made within inverso (all-D) or
retroinverso (all-D reverse) sequences [61].
Further study of these peptidic inhibitors demon-
strated that in addition to ¢brillogenesis and toxicity
inhibitory activities, they also inhibited the AL-in-
duced neurocytopathic activation of monocytes,
thus demonstrating inhibition of indirect AL toxicity
[62]. The mechanism of inhibition of monocyte acti-
vation may involve interference with internalization
rather than binding [63].
6
In a similar study, decapeptides from the AL se-
quence were synthesized and assayed for AL binding
to identify residues important for AL self-recognition
[29]. As in other similar studies, the approximate
positions of 10V20 were identi¢ed as important
and further work identi¢ed the peptide acetyl-
QKLVFF-NH2 as an AL polymerization inhibitor
(7). EM was used to observe a lack of ¢bril forma-
tion by 100 WM AL1ÿ40 in the presence of equimolar
7.
7
Soto and coworkers have described a related ap-
proach based on the AL17ÿ21 (LVFFA) region. This
strategy was based on the substitution of proline into
peptides based on AL to reduce the ability of the
peptides to adopt L-conformation [64^66]. Using
£uorescence quenching techniques, a dissociation
constant of 76 nM for the 11 residue peptide
RDLPFFPVPID, an analog of QKLVFFAEDVG
(AL15ÿ25), was determined for binding to AL1ÿ40
[61]. Using high concentrations of AL (V200 WM)
and inhibitors in high relative molar excess, ¢bril
formation was inhibited and ¢bril dissociation was
promoted. The all-D peptide was also described as
comparably inhibitory. In a subsequent study, a ¢ve
residue peptide, LPFFD, was shown to be a potent
inhibitor of AL1ÿ42 ¢brillogenesis and cellular toxic-
ity. When coinjected into rat brain with AL1ÿ42, a 20-
fold molar excess of this inhibitor reduced cerebral
amyloid deposition [65].
In an approach to inhibitor design similar to those
above, an oligolysine sequence was appended to
AL15ÿ25 to introduce a disrupting element [67]. The
resulting inhibitor reduced amyloid formation as
measured using a Th-T assay and EM, and corre-
sponding inhibition of toxicity was observed in cell
culture. Laser light scattering techniques were used
to determine that similar compounds inhibiting AL
toxicity did not prevent aggregation. Instead, the ag-
gregates detected formed with di¡erent kinetics and
had an altered structure [31].
10. Other inhibitors
A variety of additional reports describe com-
pounds that have been characterized by at least one
method to bind to AL or to inhibit its ¢brillogenesis.
For instance, polyanionic compounds have been pre-
pared as amyloid inhibitors [68^70]. In particular,
1,3-propanediol-disulfate is a potent inhibitor in a
mouse model of serum amyloid A amyloidosis. A
subsequent study showed apparent disassembly of
preformed AL1ÿ40 ¢brils when treated with a 10-
fold molar excess of this compound. These com-
pounds are very polar and limited central nervous
system availability may limit their practical applica-
tion to the treatment of peripheral amyloidoses.
Increased risk for development of AD is associated
with the presence of the O4 variant of apolipoprotein
E (ApoE) [71,72]. One proposed mechanism for the
increased risk associated with the O4 allele is that
ApoE O4 appears to be a less e¡ective inhibitor of
¢bril nucleation than the O2 and O3 variants [73^75].
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Antibodies speci¢c for AL have also been described
to inhibit ¢bril formation and to promote ¢bril dis-
aggregation [76]. Systemic dosing of an antibody
may be problematic with respect to achieving access
to and e⁄cacy in the central nervous system. The
recent report of success in vaccinating PDAPP trans-
genic mice with AL1ÿ42 emulsi¢ed with complete
Freund’s adjuvant to elicit endogenous antibodies
may o¡er a more practical though unexpected alter-
native [77].
L-Cyclodextrin (cycloheptaamylose) has been re-
ported to inhibit the cellular toxicity of AL [78].
Mass spectrometric analysis was used to infer non-
covalent complexation of cyclodextrin with AL via
interaction with hydrophobic aromatic residues on
the peptide. Moderate inhibition of toxicity to
PC12 cells was reported. Direct evidence for an e¡ect
on the state of aggregation of the AL (such as by
EM) and its correlation with cell viability was not
presented however.
Th-T is a £uorescent histological dye now well
established as a reporter molecule for amyloid poly-
merization assays [23^25]. It is a general amyloid
dye, like CR, and therefore does not represent a
speci¢c binder of AL. Unlike CR, Th-T is not re-
ported to be an inhibitor of AL polymerization but
its a⁄nity for AL may be adaptable to the develop-
ment of inhibitors. The selectivity of Th-T binding
for ¢brils suggests that the resulting compounds
might only interfere with ¢bril extension rather
than inhibit initiation of ¢brillogenesis.
Quarternary ammonium compounds were identi-
¢ed from screening a 4300 component library for
inhibition of AL polymerization. The most potent
inhibitor reported was N-hexadecyl-N-methylpiperi-
dinium bromide [26] with an IC50 in the WM range
based on nucleation assay data.
Nuclear magnetic resonance techniques have been
used to characterize the interaction of the heterocy-
clic compounds nicotine [79] and melatonin [80] with
AL. Inhibition of polymerization was not correlated
with cellular toxicity in these reports. Nicotine^AL
interactions were interpreted to suggest that a non-
pathogenic conformation of AL was stabilized. This
concept has been demonstrated in the use of a small-
molecule ligand of TTR tetramer to inhibit ¢brillo-
genic changes in conformation [81].
11. Overview
A variety of techniques have been developed to
study the polymerization of AL and they are being
applied to the development and characterization of
several classes of compounds that are potent inhib-
itors of AL polymerization (for references in addition
to those cited above, see [82]). Further reports of the
use of these compounds in increasingly robust animal
models of AD should be anticipated. An additional
area in which these various techniques and com-
pounds should prove to be useful is in the character-
ization of the mechanism of AL polymerization.
Progress in this regard will facilitate further develop-
ment of polymerization inhibitors and eventual hu-
man clinical testing. Increasing understanding in the
mechanisms by which AL is produced [83,84] and
how it interacts with other proteins in vivo [85] will
also support more re¢ned approaches to developing
improved therapeutics for AD. Observations that AL
deposits in vivo are porous and dynamical undergo
aggregation and disaggregation [86] in combination
with clinical observations that other amyloid diseases
can be treated [48,87,88] suggests that practical
therapies can be developed.
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